Argenica Therapeutics Limited (AGN.AX)

AUD 0.62

(-3.13%)

Market Cap (In AUD)

79.41 Million

Revenue (In AUD)

2.59 Million

Net Income (In AUD)

-5.47 Million

Avg. Volume

194.6 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.465-0.985
PE
-
EPS
-
Beta Value
0.734
ISIN
AU0000150328
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.
Employee Count
-
Website
https://argenica.com.au
Ipo Date
2021-06-11
Details
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.

More Stocks